ABOUT US
Pioneering novel treatment paradigms within immunology and inflammation (“I&I”). Read more about MC2 Therapeutics.
Platform
Our two first-in-class and novel mode of action drug candidates are “I&I pipeline in a drug” as they both have potential in multiple major underserved indications. We carefully select indications based on science, clinical unmet need and market access. Read more about our platform.
Pipeline
Based on our two first-in-class and novel mode of action drug candidates, we are currently pursuing indications where there are no or very limited approved treatment options. This includes MC2-32 a first-in-class oral HSP90 Inhibitor for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 a topical first-in-class iso-cyanate scavenger for Vulvar Lichen Sclerosus (Ph2a ongoing). Read more about our pipeline.
